Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated efficacy in several tumor types, including advanced ovarian cancer, breast, prostate, and pancreatic cancers. Olaparib is approved in the United States, the European Union, and other countries as maintenance treatment for women with germline or somatic BRCA-mutated advanced OC who are in response to first-line platinum-based chemotherapy based on the phase III SOLO1 study.
In this subgroup analysis, the authors evaluated the outcomes of 391 women with newly diagnosed BRCA-mutated advanced ovarian cancer receiving either olaparib or placebo maintenance as part of the multicenter, randomized, double-blind, phase III SOLO1 trial. There was a substantial progression-free survival benefit observed with olaparib regardless of the treatment and outcome (upfront surgery, interval surgery, residual disease after surgery, no residual disease after surgery) and BRCA mutation type.
Olaparib maintenance confers a substantial clinical benefit in patients with newly diagnosed advanced ovarian cancer regardless of BRCA mutation type and baseline surgery outcome.
